The UK's state-run health service said Thursday it will not offer two new treatments for Alzheimer's disease, citing high ...

The benefits from Eli Lilly’s Kisulna (donanemab) remain too small to justify the additional cost to the National Health Service (NHS), said the UK health technology assessor the National Institute ...

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has announced that Japanese ...

However, in both cases, NICE immediately published draft guidance that concluded the anti-amyloid drugs were too expensive to ...

But it said the medicines cannot be provided on the NHS because they are not good value for money and “only provide modest ...

The decision to block Alzheimer’s ‘wonder’ drugs for use by NHS patients will be appealed against. The two breakthrough drugs ...

Eli Lilly said on Thursday it would appeal against a UK agency's recommendation to not reimburse the cost of Alzheimer's drug ...

Two breakthrough Alzheimer's drugs have been deemed far too expensive, for too little benefit, to be offered on the NHS. The ...

Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s. They represent a huge step forward in research because they target a known cause of the disease, ...

A U.K. health agency said the Alzheimer's drugs Kisunla and Leqembi are not cost-effective, meaning they won't be offered through the NHS.

During a live event, Chandler H. Park, MD, and participants discuss NCCN guidelines and TiNivo-2 data for second-line renal ...